| Phenotypic Profile |
| Category |
Entity |
Quantity |
Experimental Paradigm |
Age at Testing |
| Motor phenotype |
General locomotor activity1 |
Increased
Description: Increased locomotion
Exp Paradigm: Open field test
|
Open field test |
12-16 weeks |
| |
|
Description: Increased locomotion
Exp Paradigm: Open field test |
|
|
| Motor phenotype |
General locomotor activity1 |
Decreased
Description: Decreased locomotor activity
Exp Paradigm: Open field test after administration of clozapine (3 mg/kg) i.p.
|
Open field test |
12-16 weeks |
| |
|
Description: Decreased locomotor activity
Exp Paradigm: Open field test after administration of clozapine (3 mg/kg) i.p. |
|
|
| Neuroanatomy / Ultrastructure / Cytoarchitecture |
Brain size1 |
Decreased
Description: Decreased overall brain volume; tissue contraction in cortex, entorhinal cortex, thalamus, and cerebellum
Exp Paradigm: Magnetic resonance imaging (mri) analysis
|
Magnetic resonance imaging (mri) |
12-16 weeks |
| |
|
Description: Decreased overall brain volume; tissue contraction in cortex, entorhinal cortex, thalamus, and cerebellum
Exp Paradigm: Magnetic resonance imaging (mri) analysis |
|
|
| Sensory |
Sensorimotor gating1 |
Increased
Description: Increased prepulse inhibition of acoustic startle response in response to administration of pde4 inhibitor rolipram
Exp Paradigm: Prepuluse inhibition assay performed after administration of rolipram (0.5 mg/kg) i.p.
|
Prepulse inhibition |
12-16 weeks |
| |
|
Description: Increased prepulse inhibition of acoustic startle response in response to administration of pde4 inhibitor rolipram
Exp Paradigm: Prepuluse inhibition assay performed after administration of rolipram (0.5 mg/kg) i.p. |
|
|
| Sensory |
Sensorimotor gating1 |
Increased
Description: Increased prepulse inhibition of acoustic startle response in response to administration of antipsychotics: haloperidol and clozapine
Exp Paradigm: Prepuluse inhibition assay performed after administration of clozapine (3mg/kg) and haloperidol (0.4 mg/kb) i.p.
|
Prepulse inhibition |
12-16 weeks |
| |
|
Description: Increased prepulse inhibition of acoustic startle response in response to administration of antipsychotics: haloperidol and clozapine
Exp Paradigm: Prepuluse inhibition assay performed after administration of clozapine (3mg/kg) and haloperidol (0.4 mg/kb) i.p. |
|
|
| Sensory |
Taste1 |
Decreased
Description: Decreased sucrose solution consumed as part of anhedonia, a core symptom of depression
Exp Paradigm: Sucrose preference test
|
Sucrose preference test |
12-16 weeks |
| |
|
Description: Decreased sucrose solution consumed as part of anhedonia, a core symptom of depression
Exp Paradigm: Sucrose preference test |
|
|
| Sensory |
Sensorimotor gating1 |
Decreased
Description: Decreased prepulse inhibition of acoustic startle response
Exp Paradigm: Prepulse inhibition assay
|
Prepulse inhibition |
12-16 weeks |
| |
|
Description: Decreased prepulse inhibition of acoustic startle response
Exp Paradigm: Prepulse inhibition assay |
|
|
| Sensory |
Startle response: acoustic stimulus1 |
Decreased
Description: Decreased startle response to acoustic and various other stimulus
Exp Paradigm: Response to 120db white noise stimulus
|
Acoustic startle reflex test |
12-16 weeks |
| |
|
Description: Decreased startle response to acoustic and various other stimulus
Exp Paradigm: Response to 120db white noise stimulus |
|
|
| Emotion |
Depression1 |
Increased
Description: Increased depression assayed by immobility on surface of water
Exp Paradigm: Forced swim test
|
Forced swim test |
12-16 weeks |
| |
|
Description: Increased depression assayed by immobility on surface of water
Exp Paradigm: Forced swim test |
|
|
| Emotion |
Depression1 |
Decreased
Description: Decreased depression after administration of antidepressant bupropion
Exp Paradigm: Forced swim test after administration of bupropion (4mg/kg) i.p.
|
Forced swim test |
12-16 weeks |
| |
|
Description: Decreased depression after administration of antidepressant bupropion
Exp Paradigm: Forced swim test after administration of bupropion (4mg/kg) i.p. |
|
|
| Learning & memory |
Cued or contextual fear conditioning: latent inhibition1 |
Increased
Description: Increased latent inhibition of conditioned stimulus when paired with unconditioned stimulus after administration of clozapine
Exp Paradigm: Suppression of drinking in response to noise stimulus or noise paired with foot shock after administration of clozapine (3mg/kg) i.p.
|
Fear conditioning test |
12-16 weeks |
| |
|
Description: Increased latent inhibition of conditioned stimulus when paired with unconditioned stimulus after administration of clozapine
Exp Paradigm: Suppression of drinking in response to noise stimulus or noise paired with foot shock after administration of clozapine (3mg/kg) i.p. |
|
|
| Learning & memory |
Cued or contextual fear conditioning: latent inhibition1 |
Decreased
Description: Decreased latent inhibition of conditioned stimulus when paired with unconditioned stimulus
Exp Paradigm: Suppression of drinking in response to noise stimulus or noise paired with foot shock
|
Fear conditioning test |
12-16 weeks |
| |
|
Description: Decreased latent inhibition of conditioned stimulus when paired with unconditioned stimulus
Exp Paradigm: Suppression of drinking in response to noise stimulus or noise paired with foot shock |
|
|
| Learning & memory |
Spatial working memory1 |
Decreased
Description: Decreased spatial working memory
Exp Paradigm: T-maze task
|
T-maze test |
12-16 weeks |
| |
|
Description: Decreased spatial working memory
Exp Paradigm: T-maze task |
|
|
| Emotion |
Anxiety1 |
No change |
Elevated plus maze test |
12-16 weeks |
| Learning & memory |
Spatial reference memory1 |
No change |
Morris water maze test |
12-16 weeks |
| Molecular profile |
Enzyme activity1 |
No change |
Enzyme assay |
12-16 weeks |
| Molecular profile |
Protein expression level evidence1 |
No change |
Western blot |
12-16 weeks |
| Molecular profile |
Protein expression: in situ protein expression1 |
No change |
Western blot |
12-16 weeks |
| Molecular profile |
Protein expression: in situ protein expression1 |
No change |
Western blot |
12-16 weeks |
| Sensory |
Hearing1 |
No change |
Auditory brainstem response test |
12-16 weeks |
| Sensory |
Olfaction1 |
No change |
Buried food test |
12-16 weeks |
| Sensory |
Sensorimotor gating1 |
No change |
Prepulse inhibition |
12-16 weeks |
| Social behavior |
Social interaction1 |
No change |
Three-chamber social approach test |
12-16 weeks |
|
| Not Reported: |
Circadian sleep/wake cycle, Communications, Developmental profile, Immune response, Maternal behavior, Neurophysiology, Physiological parameters, Repetitive behavior, Seizure, |
